Overview

Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study

Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the antiviral efficacy, safety and tolerability of dual therapy with 3TC and DTG as initial therapy among naïve HIV patients
Phase:
Phase 4
Details
Lead Sponsor:
Fundación Huésped
The Huesped Foundation
Collaborator:
ViiV Healthcare
Treatments:
Dolutegravir
Lamivudine